ACM
BMRN icon

ADAR1 Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

ADAR1 Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-5,000
Closed -$329K – 218
2024
Q4 		$329K Hold
5,000
– – 0.07% 131
2024
Q3 		$351K Buy
+5,000
New +$418K 0.06% 134

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ADAR1 Capital Management's BMRN Position: Q1 2026 in Review

ADAR1 Capital Management increased its BioMarin Pharmaceuticals (BMRN) stake by 41% in Q1 2026, buying an estimated $309K and bringing the position to 18,200 shares worth $1.03M. The position accounts for 0.06% of the portfolio, ranked #158.

ADAR1 Capital Management first reported a position in BMRN in Q3 2024 and has held it in 6 quarters since. 556 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

  • ADAR1 Capital Management held 18,200 shares of BioMarin Pharmaceuticals worth $1.03M as of Q1 2026.
  • ADAR1 Capital Management bought 5,300 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $309K.
  • BioMarin Pharmaceuticals made up 0.06% of ADAR1 Capital Management's portfolio in Q1 2026, its #158 holding.
  • ADAR1 Capital Management first reported a position in BioMarin Pharmaceuticals in Q3 2024 and has held it in 6 quarters since.
  • 556 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on ADAR1 Capital Management's 13F filing for Q1 2026, filed 18 May 2026.